Cinacalcet HCl in Chronic Kidney Disease Subjects With Secondary Hyperparathyroidism Not Receiving Dialysis
Completed
Amgen
Phase 3
2004-10-01
The purpose of this study is to evaluate the efficacy and safety of cinacalcet compared with
placebo in patients with stage 3 and 4 Chronic Kidney Disease (CKD).
A Research Study for Patients With End-Stage Renal Disease (ESRD)
Completed
Amgen
Phase 4
2004-05-01
The purpose of this study is to evaluate the ability of a treatment strategy, that includes
cinacalcet for the management of secondary hyperparathyroidism, to control parathyroid
hormone (PTH) compared with the standard of care.
Research Study Evaluating Cinacalcet for Patients With End Stage Renal Disease (ESRD)
Completed
Amgen
Phase 2
2003-07-01
The purpose of this study is to observe the effects of a treatment strategy that incorporates
cinacalcet HCl into the management of secondary hyperparathyroidism (HPT) in subjects with
ESRD receiving hemodialysis, on bio-intact parathyroid hormone (biPTH), corrected serum
calcium, serum phosphorus, and calcium phosphorus product.
Cinacalcet Study to Reach Kidney Disease Outcomes Quality Initiative (K/DOQI) Levels
Completed
Amgen
Phase 2
1969-12-31
The purpose of this study is to observe the effects of a treatment strategy that incorporates
cinacalcet HCl into the management of secondary hyperparathyroidism (HPT) to K/DOQI
recommended targets in subjects with end stage renal disease (ESRD) receiving hemodialysis,
on bio-intact parathyroid hormone, corrected serum calcium, serum phosphorus, and calcium
phosphorus product.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
